NL-OMON44506招募中不适用
The sIL-2R level in patients referred with a suspicion of Complex Regional Pain Syndrome. Comparison between those who are diagnosed with CRPS and those who are not. - ImPaCt
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 52
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Patients who are referred to the Center for Pain Medicine with a suspicion of CRPS.
- •Age * 18 years.
- •Only one limb is affected.
排除标准
- •History of an auto-inflammatory or autoimmune disease.
- •Current treatment with immunomodulating medication or treatment within the last 6 months.
- •Ill at the time of visit or recently been ill in the past two weeks.
- •Knowledge of or confirmed pregnancy.
研究者
相似试验
招募中
不适用
The sIL-2R level in patients referred with a suspicion of Complex Regional Pain Syndrome. Comparison between those who are diagnosed with CRPS and those who are not.Complex Regional Pain SyndromeNL-OMON20955Center for Pain MedicineDepartment of AnesthesiologyErasmus MC University Medical Center Rotterdam52
尚未招募
不适用
Association between soluble interleukin-2 receptor levels and disease severity in Complex Regional Pain SyndromeComplex Regional Pain SyndromePathophysiologyComplex Regionaal PijnsyndroomNL-OMON22217Center for Pain Medicine, Erasmus MC University Medical Center Rotterdam53
招募中
不适用
Association between soluble interleukin-2 receptor levels and disease severity in Complex Regional Pain SyndromeReflex Sympathetic DystrophyNL-OMON45772Erasmus MC, Universitair Medisch Centrum Rotterdam53
招募中
不适用
Serum leucine-rich alpha-2 glycoprotein levels for predicting ultrasonographic findings in intestinal lesion of patients with Crohn's disease in clinical remission (SAPICL study)s diseaseCrohn's diseaseJPRN-UMIN000049228Sapporo IBD Clinic100
进行中（未招募）
1 期
A double-masked study of SYL1001 in patients with moderate to severe dry eye diseaseModerate to severe dry eye disease (DED)MedDRA version: 20.0 Level: PT Classification code 10013774 Term: Dry eye System Organ Class: 10015919 - Eye disordersEUCTR2016-003903-79-SKSylentis SAU - PharmaMar Group289